Silver prices settle near a three-year high. A long bull market may be close behind.
By Myra P. Saefong
The metal's up over 9% for the week after gold's rise to a fresh record
Silver prices finished higher Thursday to notch a sixth consecutive session gain and their highest settlement in nearly 3 years.
On Comex, the most-active May silver contract (SI00) (SIK24) climbed 19 cents, or 0.7%, to settle at $27.25 an ounce, trading 9.4% higher week to date, according to Dow Jones Market Data. Prices settled at their highest since June 16, 2021.
The move in silver follows a rise in gold futures (GC00) (GCM24) to a fresh record high settlement of $2,315 an ounce on Wednesday. Based on the most-active contract, prices for the yellow metal trade more than 3% higher so far this week.
Both metals have been in demand, particularly gold, "essentially because of years of high inflation chipping away at the value of fiat currencies, which is the same reason why bitcoin has also been hitting record levels," Fawad Razaqzada, market analyst at StoneX Group's City Index and Forex.com, told MarketWatch.
Read: Veteran strategist says grab your hammer and pick - gold is headed to $3,000
"Up until a couple of weeks ago, silver wasn't finding much love," he said. "But stronger industrial data from China has boosted demand for industrial materials like copper and silver."
Forecasts from The Silver Institute show that global silver supplies are expected to mark a fourth straight year in deficit, with demand for the industrial and precious metal expected to reach its second-highest level on record this year.
Read: It may be silver's turn to shine after the gold rush to record high prices
This week, silver's rally has also been fueled by a "technical breakout above key resistance in the $25 area," said Razaqzada. That has drawn in "momentum traders who had been taking advantage of the other precious metal - gold - in recent weeks."
'Silver has a lot of catching up to do on the upside, and this week's technical breakout from a multi-year consolidation phase may well be the start of a long bull market.'Fawad Razaqzada, StoneX
Still, at these levels, "both metals appear a little overbought and a bit of a pullback should not come as surprise," he said. "That said, the big breakout in silver means traders will be happy to buy the dips moving forward."
Give all of that, Razaqzada said he expects to see more gains for silver this year, particularly because the metal has not even neared the highs of its most recent years around $30. In contrast gold has been hitting repeated all-time highs, he said.
Read: Oil, gold and the dollar are surging. Here's why that could derail the Fed's rate-cut outlook.
"Silver has a lot of catching up to do on the upside, and this week's technical breakout from a multi-year consolidation phase may well be the start of a long bull market," he said.
-Myra P. Saefong
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-04-24 1350ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track